We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
0.7500+0.0140 (+1.90%)
At close: 03:59PM EST
0.7300 -0.02 (-2.67%)
After hours: 07:45PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close0.7360
Open0.7000
Bid0.7200 x 800
Ask0.7678 x 3100
Day's Range0.6900 - 0.7500
52 Week Range0.4700 - 2.4400
Volume56,902
Avg. Volume139,226
Market Cap20.902M
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-0.9900
Earnings DateNov 13, 2023 - Nov 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EVAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evaxion Biotech A/S
    Analyst Report: Lilly(Eli) & CoEli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

    EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor Adnan Khattak will walk us through this study’s encouraging results and explain its potential for revolutionizing cancer treatment COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in th

  • GlobeNewswire

    Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

    Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 P

  • GlobeNewswire

    New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

    Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC)These new sets of clinical data further strengthen Evaxion’s position as a pioneering cancer vaccine company COPENHAGEN, Denmark, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce th

  • GlobeNewswire

    Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a letter (the “Notification Letter”) on September 29, 2023 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Compa

  • Zacks

    Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

    Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.

  • GlobeNewswire

    Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

    Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platformThe collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine Technology Transfer HubAfrigen responsible for the development and commercialization of the resulting mRNA vaccine in LMICs and African territories COPENHAGEN, Denmark, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology com

  • GlobeNewswire

    Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

    AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms EDEN™ and RAVEN™ will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogenCollaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilitiesThis collaboration underlines

  • GlobeNewswire

    Evaxion announces Executive Management Changes to strengthen the AI-strategy

    COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced: Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years. “We are truly proud to announce that

  • Insider Monkey

    Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript

    Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript August 22, 2023 Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that […]

  • Thomson Reuters StreetEvents

    Q2 2023 Evaxion Biotech A/S Earnings Call

    Q2 2023 Evaxion Biotech A/S Earnings Call